Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis

详细信息	查看全文 | 推荐本文 |

• 作者：Steve Arns ; Romelo Gibe ; Anne Moreau ; M. Monzur Morshed ; Robert N. Young ; ^{roberty@sfu.ca}
• 关键词：Prostaglandin E2 ; EP4 receptor ; Agonist ; Osteoporosis ; Conjugates ; Bone-targeting ; Alendronic acid ; Dual-action ; Anabolic ; Slow-release ; Radiolabelled
• 刊名：Bioorganic and Medicinal Chemistry
• 出版年：2012
• 期刊代码：9_09680896
• 类别：ch
• 出版时间：15 March, 2012
• 卷：20
• 期：6
• 页码：2131-2140
• 文件大小：676 K

摘要

There is an important medical need for effective therapies to redress the general bone loss associated with advanced osteoporosis. Prostaglandin E₂ and related EP4 receptor agonists have been shown to stimulate bone regrowth but their use has been limited by systemic side effects. Herein is described the design and synthesis of novel dual-action bone-targeting conjugate pro-drugs where two classes of active agents, a bone growth stimulating prostaglandin E₂ EP4 receptor subtype agonist (5 or 6) and a bone resorption inhibitor bisphosphonate, alendronic acid (1), are coupled using metabolically labile carbamate or 4-hydroxyphenylacetic acid based linkers. Radiolabelled conjugates 9, 11a/b and 25 were synthesized and evaluated in vivo in rats for uptake of the conjugate into bone and subsequent release of the EP4 agonists over time. While conjugate 11a/b was taken up (9.0%of initial dose) but not released over two weeks, conjugates 9 and 25 were absorbed at 9.4%and 5.9%uptake of the initial dose and slowly released with half-lives of approximately 2 weeks and 5 days respectively. These conjugates were well tolerated and offer potential for sustained release and dual synergistic activity through their selective bone targeting and local release of the complimentary active components.